SHENYANG, China, Feb. 11 3SBio Inc. (Nasdaq:SSRX), a leading biotechnology company focused on researching, developing,manufacturing and marketing biopharmaceutical products primarily in China,today announced that it has submitted its application for a Phase I clinicaltrial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent) withextended half-life and increased biologic activity. Pre-clinical resultsshowed a promising pharmacokinetic profile which would allow a once weeklyinjection schedule of NuPIAO in humans. NuPIAO will be investigated to treatanemia associated with both chronic kidney disease and cancer.
"This submission represents another important milestone in our effort toextend our market leading EPO franchise and continue to serve the needs ofpatients in China," said Dr. Jing Lou, CEO of 3SBio. "It is a direct result ofour dedicated R&D effort to generate an innovative pipeline and create longterm value for shareholders."
About 3SBio Inc.
3SBio Inc. is a leading, fully integrated biotechnology company focused onresearching, developing, manufacturing and marketing biopharmaceuticalproducts, primarily in China. For more information, please visit 3SBio on theweb at http://www.3sbio.com .
Safe Harbor Statement
This press release contains statements of a forward-looking nature. Thesestatements are made under the "safe harbor" provisions of the U.S. PrivateSecurities Litigation Reform Act of 1995. You can identify theseforward-looking statements by terminology such as "will," "expects,""anticipates," "future," "intends," "plans," "believes," "estimates" andsimilar statements. The accuracy of these statements may be impacted by anumber of business factors and uncertainties that could cause actual resultsto differ materially from those projected or anticipated, including factorsrelated to: the ability of 3SBio to initiate and successfully complete theregistrational trial for NuPIAO; the risk that 3SBio may not be able tocommercially offer NuPIAO in China in a timely manner or at all for whateverreason, including possible failure to obtain SFDA approval; uncertainty as tohospital or patient demand for 3SBio's products; uncertainties regarding3SBio's ability to successfully compete in the ESA market in China;uncertainties regarding 3SBio's ability to obtain favorable insurance coverageand pricing for NuPIAO, if approved by the SFDA; changes in the healthcareindustry in China, including changes in the healthcare policies andregulations of the P.R.C. government and changes in the healthcare insurancesector in the P.R.C.; fluctuations in general economic and business conditionsin China; and other risks outlined in 3SBio's filings with the Securities andExchange Commission. 3SBio does not undertake any obligation to update thisforward-looking information, except as required under applicable law.For more information, please contact: 3SBio Inc. Bo Tan Chief Financial Officer Tel: +86-24-2581-1820 Email: [email protected]
Tom Folinsbee Director of Investor Relations Tel: +852-8191-6991 Email: [email protected]
SOURCE 3SBio Inc.